<p><strong>Psyence Biomedical Ltd</strong> (NASDAQ: PBM) 的股票在周三的盘前交易中下跌。纳斯达克期货上涨 0.71%，而标准普尔 500 期货上涨 0.56%。</p>
<h2>投资者转向获利了结</h2>
<p>该股票在周四飙升超过 250% 后，目前正经历急剧回调。这一大幅反弹是由于白宫准备发布行政命令以促进对 伊博加因的研究 的消息。投资者似乎在股票近期的快速上涨后进行获利了结。</p>
<h2>特朗普行政命令提振行业</h2>
<p>此次反弹是由于总统 <strong>唐纳德·特朗普</strong> 签署了一项行政命令，以加速心理疾病治疗。该命令特别针对迷幻药物的快速审查，并包括对伊博加因研究的 5000 万美元承诺。</p>
<h2>伊博加因供应链优势</h2>
<p>Psyence Biomedical 因其符合 GMP 标准的伊博加因平台而脱颖而出。通过 PsyLabs，该公司在非洲管理原料采购、提取和纯化。Psyence 将自己定位为一个稀有的工具和设备供应商。该公司目前已持有稳定的药品级伊博加因剂量。</p>
<h2>技术分析</h2>
<p>Psyence Biomedical 仍在努力重建其长期图表，经过深度回调后，短期趋势已变得激进。</p>
<p>该股票的交易价格比其 20 日简单移动平均线（SMA）高出 115.3%，比其 100 日 SMA 高出 68.7%，这表明近期动能强劲，但也显示出 “拉伸” 距离，可能会引发反弹。</p>
<p>相对强弱指数（RSI）为 78.66，表明超买状态和更高的波动回调风险。78.66 的 RSI 显示买方近期占据主导地位，但也表明动能可能过热。</p>
<p>在过去 12 个月中，该股票下跌了 56.60%，尽管近期反弹，但整体趋势仍然脆弱。它也远低于其 52 周高点 468.36 美元，且高于 52 周低点 1.92 美元，进一步强调了波动性极大，趋势信心仍在发展中。</p>
<ul>
<li><strong>关键阻力位</strong>：$8.00 — 卖方通常首先出现的整数区域</li>
<li><strong>关键支撑位</strong>：$4.50 — 接近 20 日 EMA 区域，可能会有买入者捍卫趋势</li>
</ul>
<p><strong>PBM 股票价格活动</strong>：根据 Benzinga Pro 数据，Psyence Biomedical 的股票在周三的盘前交易中下跌 15.17%，报 8.05 美元。</p>
<p><em>图片来源于 Shutterstock</em></p>

医疗业 ETF - SPDR

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

标普全球医疗股指数 ETF - iShares

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>Psyence Biomedical 的股票在盘前交易中大幅下跌 15.17%，此前在上周四曾飙升 250%。此次下跌归因于投资者在股票快速上涨后进行获利了结。尽管近期反弹，但该股票在过去一年中仍下跌 56.60%，显示出持续的波动性。关键阻力位在 8.00 美元，而支撑位在 4.50 美元，股票在经历深度回调后正试图稳定</p>

<p><strong>Psyence Biomedical Ltd</strong> (NASDAQ: PBM) shares are trading lower in Wednesday’s premarket session. Nasdaq futures are up 0.71% while S&amp;P 500 futures have gained 0.56%.</p>
<div class="lb-trans"><p><strong>Psyence Biomedical Ltd</strong> (NASDAQ: PBM) 的股票在周三的盘前交易中下跌。纳斯达克期货上涨 0.71%，而标准普尔 500 期货上涨 0.56%。</p>
</div><h2>Investors Pivot to Profit-Taking</h2>
<div class="lb-trans"><h2>投资者转向获利了结</h2>
</div><p>The stock is currently experiencing a sharp reversal after soaring over 250% on Thursday. This massive rally was triggered by news that the White House is preparing an executive order to promote research into ibogaine. Investors appear to be engaging in profit-taking after the stock’s recent vertical climb.</p>
<div class="lb-trans"><p>该股票在周四飙升超过 250% 后，目前正经历急剧回调。这一大幅反弹是由于白宫准备发布行政命令以促进对 伊博加因的研究 的消息。投资者似乎在股票近期的快速上涨后进行获利了结。</p>
</div><h2>Trump Executive Order Boosts Sector</h2>
<div class="lb-trans"><h2>特朗普行政命令提振行业</h2>
</div><p>The rally was sparked by President <strong>Donald Trump</strong> signing an executive order to accelerate mental illness treatments. The order specifically targets faster reviews for psychedelic drugs and includes a reported $50 million commitment for ibogaine research.</p>
<div class="lb-trans"><p>此次反弹是由于总统 <strong>唐纳德·特朗普</strong> 签署了一项行政命令，以加速心理疾病治疗。该命令特别针对迷幻药物的快速审查，并包括对伊博加因研究的 5000 万美元承诺。</p>
</div><h2>Ibogaine Supply Chain Advantages</h2>
<div class="lb-trans"><h2>伊博加因供应链优势</h2>
</div><p>Psyence Biomedical stands out due to its GMP-compliant ibogaine platform. Through PsyLabs, the company manages sourcing, extraction, and purification in Africa. Psyence is pitching itself as a rare picks-and-shovels supplier. The company already holds stabilized, pharmaceutical-grade ibogaine doses in its current inventory.</p>
<div class="lb-trans"><p>Psyence Biomedical 因其符合 GMP 标准的伊博加因平台而脱颖而出。通过 PsyLabs，该公司在非洲管理原料采购、提取和纯化。Psyence 将自己定位为一个稀有的工具和设备供应商。该公司目前已持有稳定的药品级伊博加因剂量。</p>
</div><h2>Technical Analysis</h2>
<div class="lb-trans"><h2>技术分析</h2>
</div><p>Psyence Biomedical is still trying to rebuild its longer-term chart after a deep drawdown, but the short-term trend has turned aggressive.</p>
<div class="lb-trans"><p>Psyence Biomedical 仍在努力重建其长期图表，经过深度回调后，短期趋势已变得激进。</p>
</div><p>The stock is trading 115.3% above its 20-day simple moving average (SMA) and 68.7% above its 100-day SMA, which points to strong near-term momentum but also a more “stretched” distance that can invite snapback moves.</p>
<div class="lb-trans"><p>该股票的交易价格比其 20 日简单移动平均线（SMA）高出 115.3%，比其 100 日 SMA 高出 68.7%，这表明近期动能强劲，但也显示出 “拉伸” 距离，可能会引发反弹。</p>
</div><p>The relative strength index (RSI), a momentum gauge, is 78.66, which indicates overbought conditions and a higher risk of choppy pullbacks. RSI at 78.66 shows buyers have been in control lately, but it also signals momentum may be overheated.</p>
<div class="lb-trans"><p>相对强弱指数（RSI）为 78.66，表明超买状态和更高的波动回调风险。78.66 的 RSI 显示买方近期占据主导地位，但也表明动能可能过热。</p>
</div><p>Over the last 12 months, the stock is down 56.60%, which keeps the bigger-picture trend fragile despite the recent rebound. It’s also far below its 52-week high of $468.36 and above the 52-week low of $1.92, reinforcing that volatility has been extreme and trend confidence is still developing.</p>
<div class="lb-trans"><p>在过去 12 个月中，该股票下跌了 56.60%，尽管近期反弹，但整体趋势仍然脆弱。它也远低于其 52 周高点 468.36 美元，且高于 52 周低点 1.92 美元，进一步强调了波动性极大，趋势信心仍在发展中。</p>
</div><ul>
<li><strong>Key Resistance</strong>: $8.00 — a round-number area where sellers often show up first</li>
<li><strong>Key Support</strong>: $4.50 — near the 20-day EMA zone where dip-buyers may defend trend</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>关键阻力位</strong>：$8.00 — 卖方通常首先出现的整数区域</li>
<li><strong>关键支撑位</strong>：$4.50 — 接近 20 日 EMA 区域，可能会有买入者捍卫趋势</li>
</ul>
</div><p><strong>PBM Stock Price Activity:</strong> Psyence Biomedical shares were down 15.17% at $8.05 during premarket trading on Wednesday, according to Benzinga Pro data.</p>
<div class="lb-trans"><p><strong>PBM 股票价格活动</strong>：根据 Benzinga Pro 数据，Psyence Biomedical 的股票在周三的盘前交易中下跌 15.17%，报 8.05 美元。</p>
</div><p><em>Image via Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源于 Shutterstock</em></p>
</div>

为什么 Psyence Biomedical 的股票在周三下跌？